Pregnancy blood clot study aims to predict dangerous complications
NCT ID NCT07275476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how blood clotting changes in pregnant women and whether these changes can predict complications like blood clots or high blood pressure. Researchers will study 100 women aged 18-40 with natural pregnancies. The goal is to use machine learning to find hidden risk patterns and improve early detection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Two groups: 1. Healthy pregnant women 2. Pregnant women with hypertensive disorders during pregnancy
- Ages
-
18 to 40 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: I. age 18-40 years; II. natural conception (without assisted reproductive techniques). Exclusion Criteria: I. use of hormonal therapy (i.e., oral contraceptives, progestogens) within 3 months before or during pregnancy; II. use of anticoagulants oral/subcutaneous within 3 months before or during pregnancy; III. increased risk factors of VTE (i.e., obesity - body mass index \>30 kg/m2; smoking) or history of VTE; IV. Concomitant diseases, i.e: severe hypertension, diabetes mellitus, autoimmune diseases (i.e., systemic lupus erythematosus, antiphospholipid syndrome); V. congenital or acquired thrombophilia (i.e., mutation factor V Leiden, prothrombin mutation).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fibrin blood clot are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Gynecological Endocrinology Department
RECRUITINGKrakow, Małopolska, 31-501, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- How much lidocaine reaches a newborn during an urgent C-Section?
- Could pregnant patients skip clinic visits and monitor their baby from home?
- Can a video session get pregnant women to seek more health care?
- Citrulline: a potential key to prolonging pregnancy in pre-eclampsia?
- Can virtual reality coach pregnant women toward healthier habits?
- Can olive oil and nuts in early pregnancy ward off gestational diabetes?